외국의 백신 능동적 감시 시스템 소개

키워드

참고문헌 (64)

1. Samit Bhattacharyya, "The impact of rare but severe vaccine adverse events on behaviour-disease dynamics: a network model", Scientific Reports, 9(1) (2019), Springer Science and Business Media LLC[DOI]
2. Claudia Maria Trombetta, "Influenza vaccines: Evaluation of the safety profile", Human Vaccines & Immunotherapeutics, 14(3), pp.657~670 (2017), Informa UK Limited[DOI]
3. 최남경, "의약품 안전관리의 최신 국제동향", 대한의사협회지, 55(9), pp.819~826 (2012), 대한의사협회
4. "Surveillance for vaccine preventable diseases (VPDs)"[URL]
5. 김부영, "일본뇌염 백신의 이상반응 실태조사", Pediatric Infection and Vaccine, 16(2), pp.183~190 (2009), 대한소아감염학회
6. Young June Choe, "Management of vaccine safety in Korea", Clinical and Experimental Vaccine Research, 2(1), pp.40~ (2013), Korean Vaccine Society (KAMJE)[DOI]
7. Korea Centers for Disease Control and Prevention, "Epidemiology and management of vaccine preventable disease" (2017), Korea Centers for Disease Control and Prevention
8. "Sentinel Final Assessment Report" (2017)[URL]
9. G. L. Freed, "Safety of vaccinations. Miss America, the media, and public health", JAMA: The Journal of the American Medical Association, 276(23), pp.1869~1872 (1996), American Medical Association (AMA)[DOI]
10. R. T. Chen, "Vaccine Safety Datalink Project: A New Tool for Improving Vaccine Safety Monitoring in the United States", PEDIATRICS, 99(6), pp.765~773 (1997), American Academy of Pediatrics (AAP)[DOI]
11. Michael M. McNeil, "The Vaccine Safety Datalink: successes and challenges monitoring vaccine safety", Vaccine, 32(42), pp.5390~5398 (2014), Elsevier BV[DOI]
12. J. Baggs, "The Vaccine Safety Datalink: A Model for Monitoring Immunization Safety", PEDIATRICS, 127(Supplement), pp.S45~S53 (2011), American Academy of Pediatrics (AAP)[DOI]
13. Daniel Salmon, "Success Of Program Linking Data Sources To Monitor H1N1 Vaccine Safety Points To Potential For Even Broader Safety Surveillance", Health Affairs, 31(11), pp.2518~2527 (2012), Health Affairs (Project Hope)[DOI]
14. Richard Platt, "The Food and Drug Administration's Post-Licensure Rapid Immunization Safety Monitoring program: strengthening the federal vaccine safety enterprise", Pharmacoepidemiology and Drug Safety, 21, pp.291~297 (2012), Wiley[DOI]
15. R Ball, "The FDA's sentinel initiative-A comprehensive approach to medical product surveillance", Clinical Pharmacology & Therapeutics, 99(3), pp.265~268 (2016), Wiley[DOI]
16. Meghan A. Baker, "Post-licensure rapid immunization safety monitoring program (PRISM) data characterization", Vaccine, 31, pp.K98~K112 (2013), Elsevier BV[DOI]
17. Technical report In Brief: Narcolepsy in association with pandemic influenza vaccination (a multi-country European epidemiological investigation), "European Centre for Disease Prevention and Control", European Centre for Disease Prevention and Control, ~ (2012)
18. Nick Andrews, "A collaborative approach to investigating the risk of thrombocytopenic purpura after measles–mumps–rubella vaccination in England and Denmark", Vaccine, 30(19), pp.3042~3046 (2012), Elsevier BV[DOI]
19. Technical report:Narcolepsy in association with pandemic influenza vaccination (a multi-country European epidemiological investigation), "European Centre for Disease Prevention and Control", European Centre for Disease Prevention and Control, ~ (2012)
20. Eurosurveillance editorial team, "ECDC in collaboration with the VAESCO consortium to develop a complementary tool for vaccine safety monitoring in Europe", Eurosurveillance, 14(39) (2009), European Centre for Disease Control and Prevention (ECDC)[DOI]
21. Jan Bonhoeffer, "Current status and future directions of post-marketing vaccine safety monitoring with focus on USA and Europe", Biologicals, 40(5), pp.393~397 (2012), Elsevier BV[DOI]
22. Robert T. Chen, "Enhancing vaccine safety capacity globally: A lifecycle perspective", Vaccine, 33, pp.D46~D54 (2015), Elsevier BV[DOI]
23. "ADVANCE: Towards a pan-European vaccination monitoring system"[URL]
24. Laurence Torcel-Pagnon, "Guidance for the governance of public-private collaborations in vaccine post-marketing settings in Europe", Vaccine, 37(25), pp.3278~3289 (2019), Elsevier BV[DOI]
25. Xavier Kurz, "The ADVANCE Code of Conduct for collaborative vaccine studies", Vaccine, 35(15), pp.1844~1855 (2017), Elsevier BV[DOI]
26. "ADVANCE. Deliverable 1.13 White Paper" (2017)[URL]
27. "VAccine monitoring Collaboration for Europe (VAC4EU)"[URL]
28. David W Scheifele, "Immunization monitoring program, active: a model of active surveillance of vaccine safety", Seminars in Pediatric Infectious Diseases, 14(3), pp.213~219 (2003), Elsevier BV[DOI]
29. "Synopsis of a workshop on post-marketing surveillance of vaccine-associated adverse events", Can Dis Wkly Rep, 17(19), pp.97~98 (1991)
30. Bettinger JA, "Canadian IMPACT members. The Canadian Immunization Monitoring Program, ACTive (IMPACT): active surveillance for vaccine adverse events and vaccine-preventable diseases", Can Commun Dis Rep, 40(Suppl 3), pp.41~44 (2014)[DOI]
31. MacDonald NE, "Canada’s eight-component vaccine safety system: a primer for health care workers", Paediatr Child Health, 22(4), pp.e13~e16 (2017)[DOI]
32. "Deliverable 3.5 White Paper: procedures for data access, sharing, linkage and integration, including privacy and ethics" (2017)[URL]
33. Canadian Paediatric Society Infectious Diseases, "IMPACT after 17 years: lessons learned about successful networking", Paediatr Child Health, 14(1), pp.33~35 (2009)[DOI]
34. Yu-Lin Huang, "A Comparison of Active Adverse Event Surveillance Systems Worldwide", Drug Safety, 37(8), pp.581~596 (2014), Springer Science and Business Media LLC[DOI]
35. "Deliverable 5.9 White Paper" (2018)[URL]
36. "Deliverable 5.4 Final Fingerprinting of the Participating Health Care Databases" (2019)[URL]
37. "Exploring the Feasibility of Conducting Vaccine Effectiveness Studies in Sentinel’s PRISM Program (Sentinel White Paper)" (2018)[URL]
38. Tracy A. Lieu, "Health outcomes of interest for evaluation in the Post-Licensure Rapid Immunization Safety Monitoring Program", Vaccine, 30(18), pp.2824~2830 (2012), Elsevier BV[DOI]
39. Heather S. Lipkind, "Maternal and Infant Outcomes After Human Papillomavirus Vaccination in the Periconceptional Period or During Pregnancy", Obstetrics & Gynecology, 130(3), pp.599~608 (2017), Ovid Technologies (Wolters Kluwer Health)[DOI]
40. "Developing the infrastructure to conduct surveillance of birth outcomes following maternal vaccination: A Project Using Influenza Vaccines and Birth Outcomes as a Use Case (Sentinel Final Report)" (2019)[URL]
41. Richard Platt, "The U.S. Food and Drug Administration's Mini-Sentinel program: status and direction", Pharmacoepidemiology and Drug Safety, 21, pp.1~8 (2012), Wiley[DOI]
42. "Sentinel’s Distributed Database"[URL]
43. G. Trifirò, "Combining multiple healthcare databases for postmarketing drug and vaccine safety surveillance: why and how?", Journal of Internal Medicine, 275(6), pp.551~561 (2014), Wiley[DOI]
44. Preciosa M. Coloma, "Combining electronic healthcare databases in Europe to allow for large-scale drug safety monitoring: the EU-ADR Project", Pharmacoepidemiology and Drug Safety, 20(1), pp.1~11 (2011), Wiley[DOI]
45. Benedikt F.H. Becker, "CodeMapper: semiautomatic coding of case definitions. A contribution from the ADVANCE project", Pharmacoepidemiology and Drug Safety, 26(8), pp.998~1005 (2017), Wiley[DOI]
46. "Canadian Immunization Monitoring Program"[URL]
47. Wun-Ju Shieh, "2009 pandemic influenza A (H1N1): pathology and pathogenesis of 100 fatal cases in the United States", The American Journal of Pathology, 177(1), pp.166~175 (2010), Elsevier BV[DOI]
48. HENRY F. RETAILLIAU, "ILLNESS AFTER INFLUENZA VACCINATION REPORTED THROUGH A NATIONWIDE SURVEILLANCE SYSTEM, 1976–1977", American Journal of Epidemiology, 111(3), pp.270~278 (1980), Oxford University Press (OUP)[DOI]
49. Grace M. Lee, "H1N1 and Seasonal Influenza Vaccine Safety in the Vaccine Safety Datalink Project", American Journal of Preventive Medicine, 41(2), pp.121~128 (2011), Elsevier BV[DOI]
50. Greene SK, "Risk of confirmed Guillain-Barre syndrome following receipt of monovalent inactivated influenza A(H1N1)and seasonal influenza vaccines in the Vaccine Safety Datalink Project, 2009-2010", Am J Epidemiol, 175(11), pp.1100~1109 (2012)[DOI]
51. Sharon K. Greene, "Guillain-Barré Syndrome, Influenza Vaccination, and Antecedent Respiratory and Gastrointestinal Infections: A Case-Centered Analysis in the Vaccine Safety Datalink, 2009–2011", PLoS ONE, 8(6), pp.e67185~ (2013), Public Library of Science (PLoS)[DOI]
52. Yih WK, "Surveillance for adverse events following receipt of pandemic 2009 H1N1vaccine in the Post-Licensure Rapid Immunization Safety Monitoring(PRISM)System, 2009-2010", Am J Epidemiol, 175(11), pp.1120~1128 (2012)[DOI]
53. J. Dieleman, "Guillain-Barre syndrome and adjuvanted pandemic influenza A (H1N1) 2009 vaccine: multinational case-control study in Europe", BMJ, 343(jul12 2), pp.d3908~d3908 (2011), BMJ[DOI]
54. Silvana Romio, "Guillain-Barré Syndrome and Adjuvanted Pandemic Influenza A (H1N1) 2009 Vaccines: A Multinational Self-Controlled Case Series in Europe", PLoS ONE, 9(1), pp.e82222~ (2014), Public Library of Science (PLoS)[DOI]
55. A M Walker, "Diphtheria-tetanus-pertussis immunization and sudden infant death syndrome.", American Journal of Public Health, 77(8), pp.945~951 (1987), American Public Health Association[DOI]
56. Walker AM, "Neurologic events following diphtheria-tetanus-pertussis immunization", Pediatrics, 81(3), pp.345~349 (1988)
57. "Deliverable 7.7 Implementability analysis Blueprint of a framework to rapidly provide scientific evidence on post-marketing vaccination benefits and risks for informed decisions" (2018)[URL]
58. Simon J. Hambidge, "Integration of data from a safety net health care system into the Vaccine Safety Datalink", Vaccine, 35(9), pp.1329~1334 (2017), Elsevier BV[DOI]
59. Control Centers for Disease, Prevention, Practices Advisory Committee on Immunization, "Update: recommendations from the Advisory Committee on Immunization Practices (ACIP) regarding administration of combination MMRV vaccine", MMWR Morb Mortal Wkly Rep, 57(10), pp.258~260 (2008)
60. Marin M, "Use of combination measles, mumps, rubella, and varicella vaccine: recommendations of the Advisory Committee on Immunization Practices (ACIP)", MMWR Recomm Rep, 59(RR-3), pp.1~12 (2010)
61. Choe YJ, "Active surveillance of adverse events following immunization against pandemic influenza A(H1N1)in Korea", Jpn J Infect Dis, 64(4), pp.297~303 (2011)
62. HeeSoo Kim, "Post-Marketing Surveillance of Hepatitis A Virus Vaccine (Avaxim® 160U) in South Korea from 2011 to 2015", Infectious Diseases and Therapy, 8(1), pp.105~112 (2019), Springer Science and Business Media LLC[DOI]
63. Son Moon Shin, "Post-marketing safety surveillance conducted in Korea (2008–2013) following the introduction of the rotavirus vaccine, RIX4414 (Rotarix™)", Human Vaccines & Immunotherapeutics, 12(10), pp.2590~2594 (2016), Informa UK Limited[DOI]
64. 유병욱, "Phase 4, Post-Marketing Safety Surveillance of the MF59-Adjuvanted Influenza Vaccines FLUAD® and VANTAFLU® in South Korean Subjects Aged ≥65 Years", Infection and Chemotherapy, 50(4), pp.301~310 (2018), 대한감염학회[DOI]

관련 논문AI추천